Deutsche Bank
RNTX

Deutsche Bank’s Rein Therapeutics RNTX Stock Holding History

Deutsche Bank’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-6,459
Closed -$108K – 5484
2018
Q4 		$108K Buy
6,459
+5,247
+433% +$211K ﹤0.01% 4189
2018
Q3 		$67K Buy
1,212
+915
+308% +$61.6K ﹤0.01% 4626
2018
Q2 		$32K Sell
297
-51
-15% -$5.77K ﹤0.01% 4903
2018
Q1 		$56K Sell
348
-46
-12% -$8.2K ﹤0.01% 4719
2017
Q4 		$82K Buy
394
+165
+72% +$39.5K ﹤0.01% 4307
2017
Q3 		$60K Buy
+229
New +$57.4K ﹤0.01% 4324

Other funds holding RNTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JA
JOYN Advisors Atlanta, Georgia $300M AUM 14.91% 1-Year Est. Return

Deutsche Bank's RNTX Position: Q1 2019 in Review

Deutsche Bank sold out of Rein Therapeutics (RNTX) in Q1 2019, closing a stake of 6,459 shares — an estimated $108K sold.

Deutsche Bank first reported a position in RNTX in Q3 2017 and held it in 6 quarters. The position peaked at $108K in Q4 2018. 23 funds tracked by Wall St. Rank hold RNTX as of Q1 2019.

  • Deutsche Bank reported no remaining Rein Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Deutsche Bank sold 6,459 Rein Therapeutics shares in Q1 2019, an estimated $108K.
  • Deutsche Bank first reported a position in Rein Therapeutics in Q3 2017 and held it in 6 quarters.
  • Deutsche Bank's Rein Therapeutics position peaked at $108K in Q4 2018.
  • 23 funds tracked by Wall St. Rank held Rein Therapeutics as of Q1 2019.

Based on Deutsche Bank's 13F filing for Q1 2019, filed 15 May 2019.